ERBB2 and neoplasm: A study by Pierini S et al. on two immunocompromised NOD scid gamma (NSG) mouse xenograft models has demonstrated that a single dose anti-HER2 CAR-M resulted in decreased tumor burden and increased overall survival in HER2-positive SK-OV-3 tumors [52].